1. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007; 357: 2482-2494.
2. Coppinger JA, Cagney G, Toomey S, Kislinger T, et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood. 2004; 103: 2096-2104.
3. Karpatkin S. Heterogeneity of human platelets. II. Functional evidence suggestive of young and old platelets. J Clin Invest. 1969; 48: 1083-1087
4. Karpatkin S, Khan Q, Freedman M. Heterogeneity of platelet function. Correlation with platelet volume. Am J Med. 1978; 64: 542-546.
5. Bath PM, Butterworth RJ. Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis. 1996; 7: 157-161.
6. Klovaite J, Benn M, Yazdanyar S, et al. High platelet volume and increased risk of myocardial infarction: 39,531 participants from the general population. J Thromb Haemost. 2011; 9: 49-56.
7. Tavil Y, Sen N, Yazici HU, et al. Mean platelet volume in patients with metabolic syndrome and its relationship with coronary artery disease. Thromb Res. 2007; 120: 245- 250.
8. Chu SG, Becker RC, Berger PB, et al. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost. 2010; 8: 148-156.
9. Coban E, Ozdogan M, Yazicioglu G, et al. The mean platelet volume in patients with obesity. Int J Clin Pract. 2005; 59: 981-982.
10. Papanas N, Symeonidis G, Maltezos E, et al. Mean platelet volume in patients with type 2 diabetes mellitus. Platelets. 2004; 15: 475-478.
11. Hekimsoy Z, Payzin B, Ornek T, et al. Mean platelet volume in Type 2 diabetic patients. J Diabetes Complications. 2004; 18: 173-176.
12. Kakouros N, Rade JJ, Kourliouros A, et al. Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspective. Int J Endocrinol. 2011; 2011: 742719.
13. American Diabetes Association. Standards of medical care in diabetes-2018. Diabetes Care. 2018; 41 (Suppl 1): S13-S27.
14. Shirai K, Utino J, Otsuka K, et al. A novel blood pressure-independent arterial wall stiffness parameter; cardio-ankle vascular index (CAVI). J Atheroscler Thromb. 2006; 13: 101-107.
15. Nezu T, Hosomi N, Aoki S, et al. Carotid intima-media thickness for atherosclerosis. J Atheroscler Thromb. 2016; 23: 18-31.
16. Irie Y, Katakami N, Kaneto H, et al. Maximum carotid intima-media thickness improves the prediction ability of coronary artery stenosis in type 2 diabetic patients without history of coronary artery disease. Atherosclerosis. 2012; 221: 438-444.
17. den Ruijter, Peters SA, Groenewegen KA, et al. Common carotid intima-media thickness does not add to Framingham risk score in individuals with diabetes mellitus: the USE-IMT initiative. Diabetologia. 2013; 56: 1494-1502.
18. Bots ML, Groenewegen KA, Anderson TJ, et al. Common carotid intima-media thickness measurements do not improve cardiovascular risk prediction in individuals with elevated blood pressure: the USE-IMT collaboration. Hypertension. 2014; 63: 1173-1181.
19. Fujihara K, Suzuki H, Sato A, et al. Comparison of the Framingham risk score, UK Prospective Diabetes Study (UKPDS) Risk Engine, Japanese Atherosclerosis Longitudinal Study-Existing Cohorts Combine (JALS-ECC) and maximum carotid intima-media thickness for predicting coronary artery stenosis in patients with asymptomatic type 2 diabetes. J Atheroscler Thromb. 2014; 21: 799-815.
20. DeFronzo RA, Abdul-Ghani M. Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. Am J Cardiol. 2011; 108 (3 Suppl): 3B-24B.
21. Lee M, Saver JL, Hong K-S, et al. Effect of pre-diabetes on future risk of stroke: metaanalysis. BMJ. 2012; 344: e3564.
22. Dolasik I, Sener SY, Celebı K, et al. The effect metformin on mean platelet volume in diabetic patients. Platelets. 2013; 24: 118-121.
23. Peng L, Yang J, Lu X. Effects of biological variations on platelet count in healthy subjects in China. Thromb Haemost. 2004; 91: 367-372.
24. Nadar S, Blann AD, Lip GY. Platelet morphology and blood indices of platelet activation in essential hypertension: effects of amlodipine-based antihypertensive therapy. Ann Med. 2004; 36: 552-557.
25. Brown AS, Hong Y, de Belder A, et al. Megakaryocyte ploidy and platelet changes in human diabetes and atherosclerosis. Arterioscler Thromb Vasc Biol. 1997; 17: 802-807.
26. Martin JF, Trowbridge EA, Salmon G, et al. The biological significance of platelet volume: its relationship to bleeding time, platelet thromboxane B2 production and megakaryocyte nuclear DNA concentration. Thromb Res. 1983; 32: 443-460.
27. Lee RH, Bergmeier W. Sugar makes neutrophils RAGE: linking diabetes-associated hyperglycemia to thrombocytosis and platelet reactivity. J Clin Invest. 2017; 127: 2040- 2043.
28. Ueki K, Kondo T, Tseng YH, et al. Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc Natl Acad Sci U S A. 2004; 101: 10422-10427.
29. Wallenius V, Wallenius K, Ahrén B, et al. Interleukin-6-dificient mice develop mature-onset obesity. Nat Med. 2002; 8: 75-79.
30. Gieger C, Radhakrishnan A, Cvejic A, et al. New gene functions in megakaryopoiesis and platelet formation. Nature. 2012; 480: 201-208.
31. Panova NM, Arnold N, Hermanns MI, et al. Mean platelet volume and arterial stiffness-clinical relationship and common genetic variability. Sci Rep. 2017; 7: 40229.
32. Sansanayudh N, Numthavaj P, Muntham D, et al. Prognositc effect of mean platelet volume in patients with coronary artery disease. A systematic review and meta-analysis. Thromb Haemost. 2015; 114: 1299-1309.